Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome

• Main Authors: TE Morozova, TB Andruschishina, ER Kuzmina
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2014-12-01
• Series: Медицинский совет
• Subjects: артериальная гипертензия; аг; метаболический синдром; фармакотерапия аг; антигипертензивные препараты; маркеры воспаления; инсулинорезистентность; сердечно-сосудистый риск; бета-адреноблокаторы; небиволол; небилет; arterial hypertension; ah; metabolic syndrome; ah therapy; antihypertensive drugs; inflammatory markers; insulin resistance; cardiovascular risk; beta-blockers; nebivolol; nebilet
• Online Access: https://www.med-sovet.pro/jour/article/view/695
• ISSN: 2079-701X; 2658-5790

The potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily dose 5,3 ± 2,5 mg, were studied in 29 patients with stage I - II hypertension with signs of MS (men - 15, women - 14; mean age 52, 4 ± 10,32 years). Nebivolol, along with a high antihypertensive efficacy (achievement of target blood pressure in 76% of patients) and good safety profile, provides a complex effect on specific markers of inflammation and disorders of carbohydrate metabolism. The study showed a decrease in the high-sensitivity C-reactive protein (hs-CRP) from 3.15 (2.0; 4.18) mg/l to 2.3 (1.18; 4.03) mg/l (p = 0.001), intercellular adhesion molecules (iCAM-1) from 330,23 (295.7; 387.3) ng/ml to 310.07 (252.72; 370.4) ng/ml (p = 0.044) with no adverse effect on insulin resistance, as well as a reduction in the adipokine activity and overall cardiovascular risk.